trending Market Intelligence /marketintelligence/en/news-insights/trending/Fzk8oVu9eTg0Y0dsFBt6Dw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Celgene to acquire biotech firm in $300M deal

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Celgene to acquire biotech firm in $300M deal

Celgene Corp. is set to acquire privately held biotechnology firm Delinia Inc. for an initial payment of $300 million.

Delinia's shareholders are eligible for an additional $475 million in contingent payments upon achievement of certain development, regulatory and commercial milestones.

The acquisition will expand Celgene's inflammation and immunology pipeline through Delinia's lead program, DEL106, a novel IL-2 mutein Fc fusion protein that helps in the restoration of the immune system.

The transaction is expected to close in the first quarter of 2017.